• Sign In
  • Home
  • News
    • Politics
      • White House
      • Senate
      • House
      • Campaigns
  • Policy
  • Election 2025
  • Opinion
    • Editorials
    • Op-Eds
  • In Focus
  • Restoring America
  • Magazine
  • Watch
  • Sponsored
    • Examining Tax Reform
    • Fix TSCA
    • National Parks
    • Inside the Corn Belt
  • TWS Archive
Search
LogoWashington Examiner
Subscribe
LogoWashington Examiner
Sign in
Subscribe
  • News
    • Politics
      • Trump Administration
      • White House
      • Senate
      • House
      • Campaigns
    • Business
    • World
    • Investigations
    • Justice
    • Supreme Court
    • Crime
    • Entertainment
    • Washington Secrets
    • Sports
  • Policy
    • Defense
    • National Security
    • Energy and Environment
    • Education
    • Immigration
    • Finance and Economy
    • Healthcare
    • Foreign Policy
    • Tech
    • Infrastructure
    • Space
  • Election 2025
  • Government Shutdown
  • IN FOCUS
  • Opinion
    • Columnists
    • Editorials
    • Think Tanks
    • Beltway Confidential
    • Op-Eds
  • Restoring America
    • Patriotism and Unity
    • Faith, Freedom, and Self-Reliance
    • Courage, Strength, and Optimism
    • Equality, Not Elitism
    • Community and Family
    • Fairness and Justice
    • Mission
  • Watch
  • Magazine
    • Magazine
    • Quarterly Briefing
    • Archives
    • Games
  • Sponsored
    • National Parks
    • Examining Tax Reform
    • Fix TSCA
    • Inside the Corn Belt
  • Newsletters
More
    Home Authors Posts by Matthew Perrone

    Matthew Perrone

    Congress poised to pass safety-focused FDA bill
    Business

    Congress poised to pass safety-focused FDA bill

    Matthew Perrone -
    June 19, 2012 7:57 pm
    0
    FDA focuses on toxic side effects with Onyx drug
    Business

    FDA focuses on toxic side effects with Onyx drug

    Matthew Perrone -
    June 18, 2012 10:05 pm
    0
      FILE-This Tuesday, Sept. 21, 2010, file photo, shows a model of a minimally invasive heart valve by Edwards Lifesciences Corp. in Washington. The Food and Drug Administration said Monday, June 11, 2012, that the heart valve compared favorably to surgery after one year, with patients living about the same amount of time. However, reviewers said patients who got the Sapien valve had a higher rate of stroke in the month after the procedure. Additionally, more than half of patients had leaking from the aortic heart valve, a potentially dangerous condition in which blood flows backward into the heart's ventricle chamber. (AP Photo/Jacquelyn Martin, File)
    Business

    FDA reviews safety of innovative heart valve

    Matthew Perrone -
    June 11, 2012 7:30 pm
    0
    FDA delays decision on first drug to prevent HIV
    Business

    FDA delays decision on first drug to prevent HIV

    Matthew Perrone -
    June 8, 2012 10:25 pm
    0
    J&J to stop selling pelvic mesh tied to lawsuits
    Business

    J&J to stop selling pelvic mesh tied to lawsuits

    Matthew Perrone -
    June 5, 2012 5:32 pm
    0
    1...141516Page 16 of 16
    LogoWashington Examiner
    Do Not Sell or Share My Personal Information
    Facebook
    Twitter
    Youtube

    NEWS

    • Politics
      • White House
      • Senate
      • House
      • Campaigns
    • Business
    • World
    • Investigations
    • Justice
    • Supreme Court
    • Crime
    • Washington Secrets
    • Entertainment
    • Sports

    POLICY

    • Defense
    • National Security
    • Energy
    • Immigration
    • Finance and Economy
    • Healthcare
    • Foreign Policy
    • Tech
    • Infrastructure
    • Space

    COMMENTARY

    • Columnists
    • Editorials
    • Think Tanks
    • Beltway Confidential
    • Op-Eds

    RESTORING AMERICA

    • Patriotism and Unity
    • Faith, Freedom, and Self-Reliance
    • Courage, Strength, and Optimism
    • Equality, Not Elitism
    • Community and Family
    • Fairness and Justice
    • Mission
    • WATCH
    • IN FOCUS
    • NEWSLETTERS
    • MAGAZINE ARCHIVE
    • Policies and Standards
    • Terms Of Service
    • Subscription Terms of Use
    • Privacy Policy
    • Your Privacy Choices
    • Transparency In Coverage
    • Advertise
    • Subscribe
    • Contact
    • Careers
    • Staff
    • About Examiner
    • Facebook
    • Twitter